help button home button
AJRCCM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by CASTELAIN, V.
Right arrow Articles by HERVÉ, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by CASTELAIN, V.
Right arrow Articles by HERVÉ, P.

Am. J. Respir. Crit. Care Med., Volume 165, Number 3, February 2002, 338-340

Pulmonary Artery Pressure-Flow Relations after Prostacyclin in Primary Pulmonary Hypertension

VINCENT CASTELAIN, DENIS CHEMLA, MARC HUMBERT, OLIVIER SITBON, GERALD SIMONNEAU, YVES LECARPENTIER, and PHILIPPE HERVÉ

Department of Pulmonary Medicine (UPRES 2705), Antoine Béclère Teaching Hospital, Clamart, France; Cardiorespiratory Function Testing Unit, Bicêtre Teaching Hospital, le Kremlin Bicêtre, France; and Department of Thoracic and Vascular Surgery, Marie Lannelongue Teaching Hospital, le Plessis Robinson, France

Exercise tolerance improves within a few weeks after prostacyclin initiation in patients with primary pulmonary hypertension even in the absence of significant changes in resting pulmonary vascular resistance and/or in patients who fail to respond to an acute vasodilator challenge. We tested the hypothesis that this early effect of prostacyclin may be ascribable to an improved pressure-flow response of the pulmonary circulation to exercise. Pulmonary hemodynamic variables at rest and during exercise and the 6-min walking distance were determined before and after 6 wk of continuous intravenous prostacyclin treatment (11 ± 1.5 ng/kg/min) in seven patients unresponsive to an acute nitric oxide vasodilator test. Mean pulmonary arterial pressure/cardiac index coordinates obtained during exercise were pooled, and the slopes of these plots were compared using covariance analysis. All hemodynamic variables at rest were unchanged after prostacyclin. By contrast, the 6-min walking distance improved in all patients (mean increase, 81 m) and the slope of the mean pulmonary artery pressures/cardiac indexes plot decreased with prostacyclin, from 18.2 to 13.1 mm Hg/L/min/m2 (p < 0.01). These results suggest that the improvement in exercise tolerance seen after 6 wk of prostacyclin therapy may be ascribable to a decrease in incremental pulmonary vascular resistance during exercise.




This article has been cited by other articles:


Home page
 Eur Respir JHome page
A. J. Peacock, R. Naeije, N. Galie, and L. Rubin
End-points and clinical trial design in pulmonary arterial hypertension: have we made progress?
Eur. Respir. J., July 1, 2009; 34(1): 231 - 242.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
L. E. R. McLure and A. J. Peacock
Cardiac magnetic resonance imaging for the assessment of the heart and pulmonary circulation in pulmonary hypertension
Eur. Respir. J., June 1, 2009; 33(6): 1454 - 1466.
[Abstract] [Full Text] [PDF]

Home page
 Circ Heart FailHome page
S. Rich
The Effects of Vasodilators in Pulmonary Hypertension: Pulmonary Vascular or Peripheral Vascular?
Circ Heart Fail, March 1, 2009; 2(2): 145 - 150.
[Full Text] [PDF]

Home page
 Ther Adv Respir DisHome page
K. Boutet, D. Montani, X. Jais, A. Yaici, O. Sitbon, G. Simonneau, and M. Humbert
Review: Therapeutic advances in pulmonary arterial hypertension
Therapeutic Advances in Respiratory Disease, August 1, 2008; 2(4): 249 - 265.
[Abstract] [PDF]

Home page
 Eur Heart JHome page
R. Souza
Assessment of compliance in pulmonary arterial hypertension
Eur. Heart J., July 1, 2008; 29(13): 1603 - 1604.
[Full Text] [PDF]

Home page
 ChestHome page
D. Chemla and P. Herve
Estimation of Mean Pulmonary Artery Pressure: Simpler Than Expected
Chest, March 1, 2008; 133(3): 592 - 593.
[Full Text] [PDF]

Home page
 Eur Heart J SupplHome page
R. Naeije and S. Huez
Right ventricular function in pulmonary hypertension: physiological concepts
Eur. Heart J. Suppl., December 1, 2007; 9(suppl_H): H5 - H9.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart J SupplHome page
S. Huez and R. Naeije
Exercise stress tests for detection and evaluation of pulmonary hypertension
Eur. Heart J. Suppl., December 1, 2007; 9(suppl_H): H17 - H21.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart J SupplHome page
J.G. Coghlan and J. Davar
How should we assess right ventricular function in 2008?
Eur. Heart J. Suppl., December 1, 2007; 9(suppl_H): H22 - H28.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart J SupplHome page
J.-L. Vachiery and A. Pavelescu
Exercise echocardiography in pulmonary hypertension
Eur. Heart J. Suppl., December 1, 2007; 9(suppl_H): H48 - H53.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
S. Huez, F. Roufosse, J-L. Vachiery, A. Pavelescu, G. Derumeaux, J-C. Wautrecht, E. Cogan, and R. Naeije
Isolated right ventricular dysfunction in systemic sclerosis: latent pulmonary hypertension?
Eur. Respir. J., November 1, 2007; 30(5): 928 - 936.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
E. Cenedese, R. Speich, L. Dorschner, S. Ulrich, M. Maggiorini, R. Jenni, and M. Fischler
Measurement of quality of life in pulmonary hypertension and its significance
Eur. Respir. J., October 1, 2006; 28(4): 808 - 815.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
S. Ulrich, M. Fischler, R. Speich, V. Popov, and M. Maggiorini
Chronic thromboembolic and pulmonary arterial hypertension share acute vasoreactivity properties.
Chest, September 1, 2006; 130(3): 841 - 846.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
S. Holverda, C. T.-J. Gan, J. T. Marcus, P. E. Postmus, A. Boonstra, and A. Vonk-Noordegraaf
Impaired Stroke Volume Response to Exercise in Pulmonary Arterial Hypertension
J. Am. Coll. Cardiol., April 18, 2006; 47(8): 1732 - 1733.
[Full Text] [PDF]

Home page
 ChestHome page
S. Provencher, X. Jais, A. Yaici, O. Sitbon, M. Humbert, and G. Simonneau
Clinical Challenges in Pulmonary Hypertension: Roger S. Mitchell Lecture
Chest, December 1, 2005; 128(6_suppl): 622S - 628S.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
S. Provencher, X. Jais, A. Yaici, O. Sitbon, M. Humbert, and G. Simonneau
Clinical Challenges in Pulmonary Hypertension: Roger S. Mitchell Lecture
Chest, December 1, 2005; 128(6_suppl): 622S - 628S.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
A. Vonk-Noordegraaf, S. A. van Wolferen, J. T. Marcus, A. Boonstra, P. E. Postmus, J. W. L. Peeters, and A. J. Peacock
Noninvasive assessment and monitoring of the pulmonary circulation
Eur. Respir. J., April 1, 2005; 25(4): 758 - 766.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
R. Rodriguez-Roisin, M.J. Krowka, Ph. Herve, M.B. Fallon, and on behalf of the ERS Task Force Pulmonary-Hepatic
Pulmonary-Hepatic vascular Disorders (PHD)
Eur. Respir. J., November 1, 2004; 24(5): 861 - 880.
[Full Text] [PDF]

Home page
 ChestHome page
D. Chemla, V. Castelain, M. Humbert, J.-L. Hebert, G. Simonneau, Y. Lecarpentier, and P. Herve
New Formula for Predicting Mean Pulmonary Artery Pressure Using Systolic Pulmonary Artery Pressure
Chest, October 1, 2004; 126(4): 1313 - 1317.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
M. Humbert, O. Sitbon, and G. Simonneau
Treatment of Pulmonary Arterial Hypertension
N. Engl. J. Med., September 30, 2004; 351(14): 1425 - 1436.
[Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
M. M. Hoeper, R. J. Oudiz, A. Peacock, V. F. Tapson, S. G. Haworth, A. E. Frost, and A. Torbicki
End points and clinical trial designs in pulmonary arterial hypertension: Clinical and regulatory perspectives
J. Am. Coll. Cardiol., June 16, 2004; 43(12_Suppl_S): 48S - 55S.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
A. Peacock, R. Naeije, N. Galie, and J.T. Reeves
End points in pulmonary arterial hypertension: the way forward
Eur. Respir. J., June 1, 2004; 23(6): 947 - 953.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
R. J. Roeleveld, A. Vonk-Noordegraaf, J. T. Marcus, J. G. F. Bronzwaer, K. M. J. Marques, P. E. Postmus, and A. Boonstra
Effects of Epoprostenol on Right Ventricular Hypertrophy and Dilatation in Pulmonary Hypertension
Chest, February 1, 2004; 125(2): 572 - 579.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
R. T. Schermuly, K. P. Kreisselmeier, H. A. Ghofrani, H. Yilmaz, G. Butrous, L. Ermert, M. Ermert, N. Weissmann, F. Rose, A. Guenther, et al.
Chronic Sildenafil Treatment Inhibits Monocrotaline-induced Pulmonary Hypertension in Rats
Am. J. Respir. Crit. Care Med., January 1, 2004; 169(1): 39 - 45.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
M. J. Tobin
Chronic Obstructive Pulmonary Disease, Pollution, Pulmonary Vascular Disease, Transplantation, Pleural Disease, and Lung Cancer in AJRCCM 2002
Am. J. Respir. Crit. Care Med., February 1, 2003; 167(3): 356 - 370.
[Full Text] [PDF]

Home page
 Eur Respir JHome page
D. Chemla, V. Castelain, P. Herve, Y. Lecarpentier, and S. Brimioulle
Haemodynamic evaluation of pulmonary hypertension
Eur. Respir. J., November 1, 2002; 20(5): 1314 - 1331.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
O. Sitbon, M. Humbert, H. Nunes, F. Parent, G. Garcia, P. Herve, M. Rainisio, and G.e. Simonneau
Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: Prognostic factors and survival
J. Am. Coll. Cardiol., August 21, 2002; 40(4): 780 - 788.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Cell Mol. Biol.
Copyright © 2002 American Thoracic Society 		  SOTA, FL